Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals

Neurology

Volumn 72, Issue 18, 2009, Pages 1548-1554

  Alshekhlee, A ^a   Miles, J D ^a   Katirji, B ^a   Preston, D C ^a   Kaminski, H J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ETHNICITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYASTHENIA GRAVIS; MYASTHENIC CRISIS; NEUROMUSCULAR JUNCTION DISORDER; PLASMAPHERESIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPSIS; SEX DIFFERENCE; THYMECTOMY; UNITED STATES; AGE DISTRIBUTION; AGED; BREATHING MUSCLE; COHORT ANALYSIS; COMORBIDITY; HOSPITAL; INCIDENCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RACE; SEX RATIO; SKELETAL MUSCLE; STATISTICS;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; CONTINENTAL POPULATION GROUPS; FEMALE; HOSPITALS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RESPIRATORY INSUFFICIENCY; RESPIRATORY MUSCLES; SEX DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 67649414742     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a41211     Document Type: Article

References (40)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797-804.
2. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116: 2843-2854.
3. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992;42:1888-1893.
4. Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Noninvasive ventilation in myasthenic crisis. Arch Neurol 2008;65:54-8.
5. Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis 2002;4:40-42.
6. Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J 2008;101:63-69.
7. Filho J, Suarez J. Neurocritical care of myasthenia gravis crisis. In: Kaminski H, ed. Myasthenia Gravis and Related Disorders. Totowa, NJ: Humana Press; 2003:223-234.
8. Keesey JC. "Crisis" in myasthenia gravis: an historical perspective. Muscle Nerve 2002;26:1-3.
9. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505.
10. Rowland LP, Hoefer PF, Aranow H, Merritt HH. Fatalities in myasthenia gravis: a review of 39 cases with 26 autopsies. Neurology 1958;6:310-326.
11. Murthy JMK, Meena AK, Chowdary GVS, Naryanan JT. Myasthenic crisis: clinical features, complications and mortality. Neurology India 2005;53:37-40.
12. Tether JE. Management of myasthenic and cholinergic crises. Am J Med 1955;19:740-742.
13. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48:1253-1260.
14. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish populationbased study. J Neurol Neurosurg Psychiatry 1998;64: 78-83.
15. Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann NY Acad Sci 1981;377:670-677.
16. Ferguson IT, Murphy RP, Lascelles RG. Ventilatory failure in myasthenia gravis. J Neurol Neurosurg Psychiatry 1982;45:217-222.
17. Fink ME. Treatment of the critically ill patient with myasthenia gravis. In: Ropper AH, ed. Neurological and Neurosurgical Intensive Care. 3rd ed. New York: Raven Press; 1993:351-362.
18. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci 1987;505:472-499.
19. Christensen PB, Jensen TS, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology 1993;43:1779-1783.
20. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40:786-790.
21. Perlo VP, Poskanzer DC, Schwab RS, Viets HR, Osserman KE, Genkins G. Myasthenia gravis: evaluation of treatment in 1,335 patients. Neurology 1966;16:431-439.
22. Agarwal R, Reddy C, Gupta D. Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: case report and review of literature. Emerg Med J 2006;23:e6.
23. Rabinstein A, Wijdicks EFM. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology 2002;59:1647-1649.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
25. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984;70:274-284.
26. Pennington GW, Wilson A. Incidence of myasthenia gravis in the Merseyside conurbation. In: Viets HR, ed. Myasthenia Gravis. Springfield, IL: Charles C Thomas; 1961: 337-345.
27. Poulas K, Tsibri E, Papanastasiou D, et al. Equal male and female incidence of myasthenia gravis Neurology 2000;54: 1202-1203.
28. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996;47:1233-1238.
29. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989;52:1121-1127.
30. Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: Assessing the baseline adverse event rate. Crit Care Med 2002;30:2663-2668.
31. Phillips LH. The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003;998:407-412.
32. Rowland LP, Hoefer PF, Aranow H, Merritt HH. Fatalities in myasthenia gravis: a review of 39 cases with 26 autopsies. Neurology 1958;6:310-326.
33. Hill M, Ben-Shlomo Y. Neurological care and risk of hospital mortality for patients with myasthenia gravis in England. J Neurol Neurosurg Psychiatry 2008;79:421-425.
34. Mayer SA. Intensive care of the myasthenic patient. Neurology 1997;48:70-75.
35. Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry 2006;77:203- 207.
36. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629.
37. Alshekhlee A, Hussain Z, Sultan B, Katirji B. US Immunotherapy for Guillain-Barré Syndrome in the US Hospitals J Clin Neuromuscul Dis 2008;10:4-10.
38. Grosneth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 7-15.
39. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
40. Berthelsen CL. Evaluation of coding data quality of the HCUP National Inpatient Sample. Top Health Inform Manage 2000;21:10-23.